Discover
KZIA
Kazia Therapeutics Ltd ADR
14.15
1 x 14.22
1 x 14.33
bid
ask
+
0.60
4.43%
10 @ 04:00 PM
14.04 -0.11 (0.78%)
| Ytd | 105.37% | |
| 1y | 57.75% |
13.45
day range
14.30
4.86
52 week range
17.40
| Open | 13.77 | Prev Close | 13.55 | Low | 13.45 | High | 14.30 | Mkt Cap | 22.92M |
| Vol | 166.80K | Avg Vol | 207.79K | EPS | -4.76 | P/E | -2.97 | Forward P/E | N/A |
| Beta | 2.14 | Short Ratio | 0.11 | Inst. Own | 7.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-29 | 50-d Avg | 13.19 | 200-d Avg | 9.53 | 1yr Est | 19.15 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-07-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-04-11 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| 2022-08-02 | Maxim Group | Downgrade | Buy | Hold |
| 2022-08-02 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2021-10-14 | Maxim Group | Upgrade | Buy | |
| 2021-01-05 | HC Wainwright & Co. | Upgrade | Buy |
Profile
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | MAI Capital Management | 136.39K | 405.08K | 3.13% |
| 2024-09-29 | UBS Group AG | 24.95K | 74.09K | 0.57% |
| 2024-09-29 | Morgan Stanley | 22.03K | 65.42K | 0.51% |
| 2024-09-29 | Captrust Financial Advisors | 15.27K | 45.34K | 0.35% |
| 2024-09-29 | Citadel Advisors Llc | 6.05K | 17.96K | 0.14% |
| 2024-09-29 | Jane Street Group, LLC | 4.61K | 13.69K | 0.11% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 1.48K | 4.39K | 0.03% |
Dividend
| Dividend | Date |
|---|---|
| 4.0928 | 2013-01-28 |
Split
| Split | Date |
|---|---|
| 1 : 5 | 2025-04-17 |
| 1 : 10 | 2024-10-28 |
| 1 : 4 | 2017-07-14 |
| 3038 : 1000 | 2013-01-28 |
| 3.038 : 1 | 2013-01-27 |
| 0.2 : 1 | 2012-01-03 |